Ocular mucous membrane pemphigoid: Novel treatment strategies

Samir Jabbour, Maria Phylactou, Sajjad Ahmad

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewTo describe current treatments of ocular mucous membrane pemphigoid (OMMP), including conventional systemic immunosuppression (CIST) and novel biologic agents.Recent findingsCIST remains the main stay therapy for the management of OMMP. The choice of agents is tailored to disease severity - mild disease is treated with dapsone, whereas moderately severe cases are often treated with mycophenolate mofetil or sulfa-based drugs and severe cases are treated with cyclophosphamide. In recalcitrant disease newer biologics such as Rituximab, intravenous immunoglobins and tumour necrosis alpha antagonists have proven to be effective in disease control. Control of inflammation with topical therapy and halting conjunctival fibrosis remain as areas of unmet clinical needs.SummaryOMMP is largely treated with CIST. The recent introduction of new biologic agents could shape the way the disease is treated in the near future.

Original languageEnglish (US)
Pages (from-to)486-492
Number of pages7
JournalCurrent opinion in allergy and clinical immunology
Issue number5
StatePublished - Oct 1 2021
Externally publishedYes


  • blindness
  • cicatricial conjunctivitis
  • immune suppression
  • mucous membrane pemphigoid

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Ocular mucous membrane pemphigoid: Novel treatment strategies'. Together they form a unique fingerprint.

Cite this